Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00698581 · ClinicalTrials.gov registry record · Phase 3
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
A Phase 3 study, sponsored by UCB Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 88
- Enrollment target
NCT00698581 is a Phase 3 study that was terminated before completion, run by UCB Pharma. The registered enrollment target is 88 participants.
The verdict
NCT00698581, a Phase 3 study, was terminated before completion, sponsored by UCB Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 88 participants
- Enrollment target
Study Summary
Antiepileptic drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy. The objective of this study is to evaluate the efficacy of Brivaracetam (BRV) in the conversion of partial onset seizure patients from combination treatment to monotherapy
Interventions
- DRUG Brivaracetam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00698581
The ClinicalTrials.gov registry entry for NCT00698581 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brivaracetam is the first listed.
NCT00698581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00698581 about?
NCT00698581 is a clinical study titled "A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures". Antiepileptic drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy. The objective of this study is to evaluate the efficacy of Brivaracetam (BRV) in the conversion of partial onset seizure patients from combination treatment to ...
What is the current status of trial NCT00698581?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 88 participants. The study started on 2008-08. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00698581?
The interventions under investigation include: Brivaracetam (DRUG).
Who is sponsoring clinical trial NCT00698581?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.